Kymera Therapeutics Soars as Sanofi Expands Studies of Its Skin Diseases Drug

Key Takeaways Shares of Kymera Therapeutics (KYMR) jumped Tuesday, a day after it said partner Sanofi (SNY) agreed to extend a Phase 2 trial of its experimental drug to treat certain autoimmune skin diseases. KT-474 is being studied as a treatment for patients suffering from hidradenitis suppurativa and atopic dermatitis. It targets a key protein that plays a critical role in triggering the immune system response against invading pathogens. The two companies announced their partnership in 2020, with Kymera ...